Drug Patents owned by Endo Pharms Inc

1. Drug name - AVEED

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels Mar, 2027

(4 years from now)

US8338395 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels May, 2027

(4 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired); hypogonadotropic hypogonadism (congenital or acquired).

Dosage: INJECTABLE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
750MG/3ML (250MG/ML) INJECTABLE;INTRAMUSCULAR Prescription

2. Drug name - MEGACE ES

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107827 ENDO PHARMS INC Nanoparticulate megestrol formulations Apr, 2024

(1 year, 6 months from now)

US9101549 ENDO PHARMS INC Nanoparticulate megestrol formulations Apr, 2024

(1 year, 6 months from now)

US9101540 ENDO PHARMS INC Nanoparticulate megestrol formulations Apr, 2024

(1 year, 6 months from now)

US9040088 ENDO PHARMS INC Nanoparticulate megestrol formulations Apr, 2024

(1 year, 6 months from now)

US7101576 ENDO PHARMS INC Nanoparticulate megestrol formulations Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using MEGESTROL ACETATE ingredient

Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
125MG/ML SUSPENSION;ORAL Prescription

3. Drug name - NASCOBAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940714 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Feb, 2024

(1 year, 4 months from now)

US7404489 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Mar, 2024

(1 year, 5 months from now)

US9415007 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Jul, 2024

(1 year, 9 months from now)

US7229636 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Aug, 2024

(1 year, 9 months from now)

US7879349 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Aug, 2024

(1 year, 9 months from now)

US8003353 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Aug, 2024

(1 year, 9 months from now)

Drugs and Companies using CYANOCOBALAMIN ingredient

Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.5MG/SPRAY SPRAY, METERED;NASAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.